Anti-PM/Scl antibody-positive myositis with muscle pathology resembling anti-synthetase syndrome
Clicks: 1
ID: 320765
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #37 of 43 articles by views in Modern Rheumatology Case Reports
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Anti-PM/Scl antibodies were originally thought to be autoantibodies associated with overlap syndromes involving idiopathic inflammatory myopathies (IIM) and systemic sclerosis (SSc), but some patients with these antibodies present with clinical features similar to those of anti-synthetase syndrome (ASyS). Herein, we report the case of a 63-year-old Japanese woman with anti-PM/Scl antibody-positive, but anti- aminoacyl tRNA synthetases (anti-ARS) antibody-negative myositis with interstitial lung disease (ILD) and dermatomyositis-like skin manifestations. Her muscle pathological findings resembled those observed in ASyS, including perifascicular fibre necrosis and increased alkaline phosphatase (ALP) activity in the perimysium. Owing to the potential risk of SSc overlap and scleroderma renal crisis (SRC), calcineurin inhibitor (CNI) treatment was avoided, and mycophenolate mofetil (MMF) was administered in addition to glucocorticoids. This approach enabled rapid tapering of glucocorticoids, resulting in a favourable clinical course. To our knowledge, this report provides novel insights into the muscle pathology of anti-PM/Scl antibody-positive myositis, highlighting pathological similarities with ASyS. Our findings also suggest that MMF may be a reasonable immunosuppressive therapy, especially when there is a risk of SRC.
| Reference Key |
openalex_W7168106433
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Kosuke Naito, Mayu Yagita-Sakamaki, Atsuko Nishikawa, Toshio Tanaka |
| Journal | Modern Rheumatology Case Reports |
| Year | 2026 |
| DOI |
10.1093/mrcr/rxag065
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.